SCHEMBL18174199

SCHEMBL18174199

CC(Cc1ccc(OC(F)F)c(Cl)c1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.49
PPARA Q07869 6/20 0.49
MEN1 O00255 5/20 0.49
LMNA P02545 5/20 0.49
HTT P42858 5/20 0.49
KMT2A Q03164 5/20 0.49
ALDH1A1 P00352 3/20 0.49
PPARD Q03181 3/20 0.49
P2RX3 P56373 1/20 0.48
CSNK2A1 P68400 2/20 0.47
TP53 P04637 1/20 0.46
HTR1E P28566 1/20 0.46
S1PR3 Q99500 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.43
RAB9A P51151 2/20 0.43
GAA P10253 1/20 0.43
XBP1 P17861 1/20 0.43
CCR6 P51684 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18182095 0.83 CSNK2A1 (0.53) MAPTMEN1LMNAHTTKMT2A
SCHEMBL16913143 0.82 P2RX3 (0.48) PPARAPPARDP2RX3LDHARORC
SCHEMBL20128503 0.81 CSNK2A1 (0.50) MAPTMEN1LMNAHTTKMT2A
SCHEMBL6005581 0.80 PNMT (0.58) PPARAPPARDSMN1; SMN2PPARG
SCHEMBL5130053 0.80 PNMT (0.58) PPARAPPARDSMN1; SMN2PPARG
SCHEMBL10274466 0.80 CSNK2A1 (0.51) MAPTMEN1LMNAHTTKMT2A
SCHEMBL6003855 0.80 PNMT (0.58) PPARAPPARDSMN1; SMN2PPARG
SCHEMBL16322462 0.78 EPHX1 (0.47) PPARAPPARDP2RX3LDHARORC
SCHEMBL23964692 0.77 CA2 (0.57) MAPTPPARAMEN1LMNAKMT2A
SCHEMBL21895817 0.77 ACACB (0.53) PPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10118920-B2 Isoxazolyl substituted benzimidazoles CELLCENTRIC LTD (GB) 2018-11-06 US disclosed
US-20180127402-A1 ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES CELLCENTRIC LTD (GB) 2018-05-10 US disclosed
CN-107750249-A The benzimidazole of isoxazolyl substitution 塞尔森瑞科有限责任公司 2018-03-02 CN disclosed
EP-3286183-A1 ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES Cellcentric Ltd (GB) 2018-02-28 EP disclosed
WO-2016170324-A1 ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES CELLCENTRIC LTD (GB) 2016-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180127402-A1 ISOXAZOLYL SUBSTITUTED BENZIMIDAZOLES EP300, HDAC3, HDAC1 MAPT 4059/4885PPARA 1521/4885MEN1 3014/4885
US-10118920-B2 Isoxazolyl substituted benzimidazoles EP300, HDAC3, HDAC1 MAPT 4059/4885PPARA 1521/4885MEN1 3014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.